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Abstract 
Background: Schizophrenia remains a priority condition in mental health policy and service development because 
of its early onset, severity and consequences for affected individuals and households.
Aims and methods: This paper reports on an ‘extended’ cost-effectiveness analysis (ECEA) for schizophrenia treat-
ment in India, which seeks to evaluate through a modeling approach not only the costs and health effects of inter-
vention but also the consequences of a policy of universal public finance (UPF) on health and financial outcomes 
across income quintiles.
Results: Using plausible values for input parameters, we conclude that health gains from UPF are concentrated 
among the poorest, whereas the non-health gains in the form of out-of-pocket private expenditures averted due to 
UPF are concentrated among the richest income quintiles. Value of insurance is the highest for the poorest quintile 
and declines with income.
Conclusions: Universal public finance can play a crucial role in ameliorating the adverse economic and social conse-
quences of schizophrenia and its treatment in resource-constrained settings where health insurance coverage is gen-
erally poor. This paper shows the potential distributional and financial risk protection effects of treating schizophrenia.
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Background
Schizophrenia poses a considerable public health and 
social policy challenge because of its severity, its often 
catastrophic effect on the welfare and income of family 
members and the significant risk that patients will suffer 
severe human rights violations. The provision and effec-
tive coverage of care and treatment for severe mental 
disorders such as schizophrenia in India is limited, both 
in terms of access to services and financial protection or 
insurance. Efforts to scale up community-based public 
mental health services can contribute strongly to greater 
equality of access, since such services will serve more 
people in need and with less reliance on direct out-of-
pocket spending.
This paper considers this claim through an innova-
tive approach to economic evaluation called ‘extended 
cost-effectiveness analysis’ [1]. ECEA goes beyond con-
ventional cost-effectiveness analysis (CEA) by not only 
considering the distribution of costs and outcomes 
across different socioeconomic groups in the popula-
tion, but also by explicitly examining the extent to which 
interventions or policies protect households against the 
financial risk of medical impoverishment [1, 2]. Taking 
into account current debates in India about appropriate 
pathways towards universal health coverage, we focus 
in this paper on the impact of enhanced public financ-
ing and provision of schizophrenia treatment on health 
and financial outcomes, including increased uptake of 
treatment (leading to more health gain), reduced out-
of-pocket treatment costs and greater insurance against 
catastrophic health expenses. Assessment of these vari-
ous consequences provides new, evidence-based insights 
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to national policy makers responsible for setting priori-
ties and allocating resources in the health sector.
ECEA builds on the evidence already generated 
through the standard application of cost-effectiveness 
analysis to schizophrenia treatment in resource-con-
strained developing countries, in which the focus is 
on the relative costs per unit of health gain. Patel et  al. 
reviewed the cost-effectiveness of select mental disorders 
and conclude that first-generation antipsychotic drugs in 
low-income and middle-income countries and their ben-
efits can increase through psychosocial treatments at the 
community level [3]. Chisholm et  al. analyzed the cost-
effectiveness of first- and second-generation antipsy-
chotic drugs—alone or in combination with psychosocial 
counseling—in Chile, Nigeria and Sri Lanka and found 
that community-based outpatient provision of older 
(first-generation) antipsychotic drugs and psychosocial 
treatment is the most cost-effective intervention. More-
over, the estimated cost of increasing treatment cover-
age through a community-based service model together 
with efficient treatment options is very low (investment 
of <Int.$1 per capita) [4]. Chisholm and Saxena evalu-
ated the comparative costs and effects of a package of 
interventions in sub-Saharan Africa and Southeast Asia 
for a cluster of five neuropsychiatric conditions, includ-
ing schizophrenia and found that neuroleptic antipsy-
chotic drugs and psychosocial treatment were the most 
cost-effective intervention for schizophrenia [5]. Phan-
thunane et  al. surveyed patients seeking treatment for 
schizophrenia in Thailand to provide detailed breakdown 
of the costs involved in schizophrenia treatment includ-
ing health care costs and productivity losses to patients 
and families [6]. In Kenya, de Menil et al. find that a com-
munity based intervention is cost-effective and achieves 
increasing returns over time but may not be affordable 
for the Kenyan government [7]. Cost-effectiveness stud-
ies on chronic schizophrenia treatments have also com-
pared the efficacy of typical (first-generation) versus 
atypical (newer) drugs in low-resource settings, such as 
China and Thailand [8, 9]. Clinical studies from high-
income country settings evaluate cost-effectiveness and 
compliance rates of first- versus second-generation antip-
sychotic drugs using pharmaco-economic analysis and 
find the latter to have a higher cost-effectiveness and bet-
ter safety profile [10, 11].
Methods
Analytical approach
We constructed an equation-based, static (single year) 
model of the expected costs, health outcomes and finan-
cial risk protection effects (including averted private 
out-of-pocket expenditures) associated with a policy of 
enhanced public financing of schizophrenia treatment in 
India. While UPF in India has previously been available 
for specific diseases such as AIDS, it has recently moved 
toward secondary and tertiary care insurance coverage in 
the form of programs such as Rashtriya Swasthya Bima 
Yojana aimed at providing financial protection against 
catastrophic health expenses. However, such schemes 
currently exclude treatment of mental disorders and con-
sequently, there has been no quantitative assessment of 
the amount of financial protection that a UPF scheme can 
provide against schizophrenia treatment. Since this is the 
first application of ECEA to be carried out in the context 
of mental disorders, our first goal was to test its applica-
bility and assess its internal validity. We accomplished 
this by constructing a series of equation-based ECEA 
models that employed the same epidemiological and 
treatment cost-outcome input data used in previous CEA 
studies in the context of South-East Asia [5]. Additional 
information output from the ECEA model—particularly 
the estimated value of financial risk protection arising 
from public financing of health care costs—could then 
be readily interpreted with reference to this earlier pub-
lished work. We subsequently adapted or updated model 
input parameters to better reflect the current situation 
and evidence base for schizophrenia treatment in India 
(the model is available from the authors on request).
Interventions modeled
In this model, all persons treated for schizophrenia in 
non-specialized health care settings receive a combina-
tion of first-generation antipsychotic drugs as well as 
basic—or, for a small proportion, intensive—psychosocial 
treatment. First-generation antipsychotic medication is 
either tablet doses of haloperidol-chlorpromazine or an 
injection of fluphenazine, with biperiden administered 
for side effects. The second-generation antipsychotic 
medication considered is tablets of risperidone. We use 
a weighted average of these anti-psychotic medications 
with basic psychosocial treatment as a single treatment 
package. After the implementation of UPF, 80  % of the 
population that needs treatment would receive pub-
licly financed care (target coverage). The average treat-
ment coverage rate for schizophrenia is 40  % based on 
a World Health Survey study from 2003 on coverage of 
schizophrenia treatment in 6 states in India [12]. Due 
to increased detection and healthcare utilization rates 
among the richer socioeconomic groups, we distrib-
ute the coverage rates to range from 30 % in the poorest 
income group to 50 % in the richest.
Treatment costs
For this model, all patients treated for schizophrenia 
are assumed to receive a combination of antipsychotic 
drugs and basic psychosocial treatment; 90  % receive 
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haloperidol or chlorpromazine with biperiden (for side 
effects) and the remaining 10  % receive a fluphenazine 
injection. Fifteen percent are assumed to receive inpa-
tient psychiatric care in a short-term community-based 
psychiatric unit, 2  % are long-term community-based 
residential patients and 50  % have outpatient visits (for 
follow-ups) [13]. Finally, 10  % of treated patients are 
modeled to receive more intensive, individual-based psy-
chological treatment. Table 2 presents the costs of all the 
treatment resources used as inputs in the model. Average 
per unit treatment costs are sourced from the mhGAP 
costing tool for India, based on the study site of Sehore 
district in Madhya Pradesh, India. The mhGAP cost-
ing tool values tradable healthcare goods such as medi-
cines and diagnostic equipment at international prices 
adjusted for shipping and distribution costs. Default 
drug prices are from the International Drug Price Indi-
cator Guide. Costs of non-tradeable healthcare goods in 
the form of local personnel, in-patient and out-patient 
care, consumables, building costs and utilities are pre-
dicted using the WHO-CHOICE costing database [13]. 
As Table  2 indicates, the average annual schizophrenia 
treatment cost per case under a policy of universal public 
finance is approximately $177 (2012 USD). This does not 
include direct non-medical costs such as transport, time 
and opportunity costs.
Health impacts
We use disability-adjusted life years (DALYs) as the health 
outcome to evaluate the consequences of enhanced pub-
lic financing for schizophrenia treatment. However, since 
schizophrenia treatment is accorded with no direct mor-
tality effect, DALYs were estimated using the prevalent 
YLD method:
Data on schizophrenia prevalence rates are from the 
Global Burden of Disease study’s 2010 DisMod-MR out-
put [14]. These rates are stratified by region, age group 
and gender. Disability weights for residual and acute 
cases are 0.576 and 0.756 respectively, where zero refers 
to no disability [15]; we use a weighted average composite 
disability weight based on time spent in a state of acute 
(20 %) versus residual (80 %) schizophrenia, where acute 
specifically refers to time spent in a continuous florid 
state (typically lasting 4–8 weeks). Our definition of acute 
schizophrenia and the associated distribution of time 
spent in this acute state is different to that reported by 
Ferrari et al. [16] who estimate on the basis of six stud-
ies that 63  % of cases (not time spent) are acute and 
only 37 % of cases are residual. Our composite disability 
YLD = prevalent cases ∗ (effect size ∗ adherence)
∗ disability weight ∗ average duration of disability
∗ target coverage
weight of 0.61 is very much in line with WHO and other 
previous estimates of the average level of disability asso-
ciated with schizophrenia. To calculate improvements 
in disability compared to (untreated) natural history, 
treatment effect sizes reported in the literature were 
converted into an equivalent change in disability weight 
[4]; this resulted in a proportionate improvement in the 
disability weight of 24 % [13, 17, 18]. Adherence to treat-
ment is set to be 76 % for treatment with first- or second-
generation mediation [19].
Value of insurance
Following Verguet et  al. [1] we calculate the expected 
value of a gamble concerning the cost of treating schizo-
phrenia without UPF at the individual level, as follows:
 where p  =  overall probability of receiving care for 
schizophrenia (calculated as, coverage*prevalence rates 
per quintile), c = treatment cost and y =  income. Risk 
aversion is used here as a characteristic of people’s 
utility function. Specifically, to estimate financial risk 
protection of the policy, we first estimated the individ-
ual’s expected income before public financing, which 
depends on treatment coverage and associated out-
of-pocket costs. An individual’s certainty equivalent is 
then estimated by assigning individuals a utility func-
tion that specifies their risk aversion, which is equiva-
lent to calculating their willingness to pay for insurance 
against the risk of medical expenditure. The certainty 
equivalent, assuming a coefficient of relative risk aver-
sion r, is
 Money metric value of insurance v(p, y, c) at the individ-
ual level is then
 The total insurance value per quintile of income is
where target coverage is assumed to be 80 %. The value of 
3 is considered to be an appropriate, conservative level of 
risk aversion [20, 21].
Analysis of the distribution of costs and effects 
across income groups
To perform a quintile-based income analysis, we assume 
an evenly distributed cohort size of 200,000 individu-
als in a population of 1 million. Concerning prevalence, 
we apply DisMod’s epidemiological indicators for South 
Asia to a large household survey in India: Round 3 of the 















�(v) ∗ quintile size ∗ target coverage
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District Level Household and Facility Survey [22]. DLHS-
3, conducted in 2007–08, is a nationally representative 
data set on reproductive and child health indicators, cov-
ering 720,320 households and over 3.7 million individuals 
from 601 districts across India [22]. The survey reports 
demographic information (age, gender, socioeconomic 
status) for each member of the household and also com-
putes a wealth quintile for each individual based on her 
household’s composition of owned assets. To each such 
individual in the DLHS-3 sample, we assign the relevant 
schizophrenia prevalence rate from DisMod, based on 
the individual’s age and gender. Thus, the DLHS-3 sample 
now has information on every individual’s prevalence rate 
for schizophrenia, besides her gender, age in completed 
years and wealth quintile. Using sampling weights, we 
then derive a weighted average prevalence rate for each 
income quintile, assuming the DLHS-3 wealth quintiles 
are a good approximation of the income quintile distri-
bution in India. The prevalence rates per income quintile 
are presented in Table 1. As seen in the table, these rates 
increase with higher income groups. This is a reflection 
of the demographic composition of the DLHS-3 sam-
ple. Data from DisMod indicates that the age-group with 
the highest rate of prevalence is 20–24 years followed by 
25–34  years for both males and females. Demographic 
composition of the DLHS-3 sample suggests that propor-
tions of these two high-prevalence age groups increase 
with higher income quintiles; individuals in these age-
groups together constitute 20  % of the poorest quintile, 
22 % of the second quintile, 24 % of the middle quintile, 
26 % of the richer quintile and 28 % of the richest quin-
tile. Thus, the observed increase in prevalence rates with 
income is because the relative sample shares of the age-
groups with the highest prevalence rates increase with 
income owing to the demographic composition of the 
survey data.
For calculating current average monthly per capita 
gross domestic product (GDP) per income quintile, we 
used the World Bank’s Poverty Calculation Net (PovCal-
Net) tool [23], which reports the share of each decile as 
a proportion of the total monthly consumption of India 
based on a sample of households surveyed in 2009. The 
consumption shares by decile are based on estimated 
Lorenz curves; households are ranked by consumption 
per person and distributions are population (household 
size and sampling expansion factor) weighted. Based on 
the consumption shares, which range from 3.7 % in the 
lowest decile to 28.8  % in the highest decile, we create 
a multiplier for each quintile based on its relative share 
of consumption. This is done by taking each quintile’s 
percentage share of consumption and dividing it by the 
average percentage share across all the quintiles. This 
gives us a relative weight for each quintile that is further 
multiplied by the annual GDP per capita of $1500 (cur-
rent USD) to calculate the average annual GDP per capita 
for each quintile, which ranges from $641 in the poorest 
quintile to $3211 in the richest quintile (Table 1) [23].
To evaluate the consequences of UPF for private (OOP) 
expenses toward schizophrenia treatment, we first esti-
mate the quintile-specific total treatment costs under 
Table 1 Parameters used for UPF of schizophrenia treatment and their corresponding sources
Input Value Source
Demography
Cohort size 1,000,000 Authors’ assumption
Cohort size per quintile 200,000 Authors’ assumption
Treatment impact
 a. Population-wide
  Coefficient of relative risk aversion 3 [20, 21]
  Disability weight (residual state) 0.576 [15]
  Disability weight (acute state) 0.756 [15]
  Treatment effectiveness (anti-psychotic medication  
+ psychosocial treatment)
24 % [5]
  Treatment adherence rate 76 % [19]
 b. Quintile-specific I II III IV V
  Current coverage 30 % 35 % 40 % 45 % 50 % [27]
  Target coverage 80 % 80 % 80 % 80 % 80 % Authors’ assumption
  Prevalence rates per quintile 0.25 % 0.26 % 0.27 % 0.29 % 0.32 % [14, 22]
  Overall probability of seeking care 0.08 % 0.09 % 0.11 % 0.13 % 0.16 % Authors’ calculations
Income
Average monthly GDP per capita income (current USD) $641 $911 $1177 $1562 $3211 [23]
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current coverage rates as well as under the scenario 
where UPF targets 80 % coverage. We assume that at least 
70 % of the total treatment costs are borne OOP by indi-
viduals across all quintiles [24, 25]. We then estimate the 
quintile-specific OOP expenses incurred by individuals 
in the absence of UPF and those averted under UPF’s tar-
get coverage of 80 %. We also report the additional costs 
to the government from providing UPF across quintiles.
Results
Cost‑effectiveness
In this section, we present quintile-based outcomes of 
standard cost-effectiveness of UPF relative to the cur-
rent treatment scenario for schizophrenia, where treat-
ment is a combination of first- and second-generation 
antipsychotic medication with basic psychosocial treat-
ment (Table  3). Regarding health gains from UPF: 
extending schizophrenia treatment from baseline cover-
age rates (ranging from 30 to 50 % across quintiles) to a 
target coverage rate of 80 % for all quintiles under UPF, 
averts an extra 22 to 28 DALYs per quintile population 
of 200,000 persons, for a total of 122 averted DALYs per 
one million population. The estimated burden of disease 
per one million population is 1704 DALYs and the cur-
rently averted burden is 126 DALYs, so this is equivalent 
to doubling the averted burden (from 7 to 14 % of dis-
ease burden).
As seen in Table  2, the total annual cost of treatment 
per case is USD $177.42. In the absence of UPF, the 
total annual costs of treatment per quintile range from 
$26,721 in the poorest to $57,059 in the richest quintile. 
Extending treatment to 80 % of the population increases 
the total annual treatment costs, ranging from $71,257 
in the poorest quintile to $91,295 in the richest quintile. 
The cost per capita is $0.36 for the poorest quintile and 
$0.46 for the richest quintile. This yields a cost- effec-
tiveness ratio of USD $1589 per DALY averted for each 
income quintile. The cost-effectiveness ratio is stable 
across income groups because the extra cost associated 
with reaching target coverage in the lower income quin-
tiles is offset by a commensurate improvement in health 
outcomes (Table 2).
As discussed earlier, in the absence of UPF, private 
individuals in India incur a large share of total treat-
ment costs. With UPF, this cost burden will be trans-
ferred to the government. The impact of UPF on private 
costs averted is shown in Table 3. The total OOP private 
expenditure averted due to UPF is estimated at $276,623. 
Moreover, it increases across income quintiles, ranging 
from $49,880 for the poorest quintile and $63,906 for the 
richest quintile. OOP expenditures are mainly a function 
of prevalence rates, coverage rates and the percentage 
share of health expenses that are out-of-pocket and unit 
cost per case. Since unit cost of treatment per case ($177. 
4) and the percentage of total expenses that are paid 
OOP (70  %) are assumed constant across all quintiles, 
this upward trend in OOP expenses averted from UPF is 
mainly a reflection of average prevalence rates rising with 
income and the gradient of current coverage rates across 
quintiles as seen in Table 1.
Table 2 Treatment resource costs and shares of out-of-pocket (OOP) private expenditure
Treatment resource costs % of cases  
needing






I. Primary health center
Anti-psychotic medication primary care visits 100 4 1.78 7.12
Basic psychosocial treatment 100 6 1.78 10.68
Intensive psychosocial treatment 10 18 5.56 10.01
II. Hospital
Outpatient visits for short term inpatients 50 12 2.51 15.06
Inpatient treatment- psychiatric unit-short term 15 28 8.83 37.09
Inpatient treatment- residential unit-long term 2 180 8.47 30.49
III. Drug
Chlorpromazine 25 1095 0.01 3.67
Haloperidol 50 584 0.00 1.17
Risperidone 10 913 0.07 7.95
Fluphenazine 10 12 0.60 0.96
Biperiden 10 70 0.10 0.94
IV. Other
Lab tests 50 1 5.00 2.50
Total cost per case (2012 USD/year) 177.42
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Under this scenario, if 80 % of a population of one mil-
lion is targeted for coverage through UPF, the govern-
ment must meet a total cost of $395,176 per one million 
individuals.
Figure  1 compares the quintile distribution of pub-
lic health spending on schizophrenia treatment under 
current coverage (ranging from 30 to 50 %) versus that 
under UPF’s target coverage of 80 %. Under current cov-
erage, distribution of public health spending accords 
with evidence in Mahal et  al. of a regressive pattern of 
health spending that disproportionately favors the rich; 
this is mainly a manifestation of higher treatment cov-
erage rates among the richer groups [24]. Introduction 
of UPF flattens this distribution, thus creating distribu-
tional consequences of universalizing healthcare cover-
age and costs.
Value of insurance
An additional financial consequence of a health inter-
vention such as UPF is the money metric value of insur-
ance, which is the amount an individual is willing to pay 
to receive risk protection i.e., to be in a healthy state 
Table 3 Results
UPF = universal public financing for 80 % of population in need. Results are based on a population of 1 million people, with intervention benefits equally divided 
among income quintiles of 200,000 persons each (quintile I having the lowest household income and quintile V, the highest). “Target coverage” of UPF for 
schizophrenia treatment for all income groups was set at 80 %. All monetary values or costs are expressed in U.S. 2012 dollars. “Total costs” = (direct government 












YLD (current burden) 307 316 333 354 394 1704
DALY averted by UPF (averted 
burden)
28 26 24 23 22 122
Current coverage
Total costs of treatment ($) 26.721 32.042 38.666 46.156 57.059 200.644
Private costs of treatment ($) 18.705 22.429 27.066 32.309 39.942 140.451
Current costs met by government 
($)
8.016 9.613 11.600 13.847 17.118 60.193
Target coverage (under UPF)
Total costs of treatment ($) 71.257 73.238 77.331 82.055 91.295 395.176
Additional costs to government ($) 44.535 41.196 38.666 35.899 34.236 194.532
OOP expenses averted ($) 49.880 51.267 54.132 57,439 63,906 276.623
Cost-effectiveness ratio (Cost/
DALY averted) ($)
1.589 1.589 1.589 1.589 1.589























Fig. 1 Distribution of spending on schizophrenia treatment
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vis-à-vis a poor health state. The total annual value of 
insurance from UPF for the entire population of 1 mil-
lion is USD $24,582. The value is the highest for the 
lowest income quintile and decreases as income rises. 
The annual insurance value for the poorest quintile is 
USD  $7282, which is approximately 30  % of the total 
value (Fig. 2). The second income quintile has an annual 
insurance value of USD $5587; the third income quintile, 
$4972; and the fourth income quintile, $4302. The high-
est income quintile has an annual insurance value of USD 
$2439, which is approximately 10 % of the total value.
Uncertainty analysis
To test the reliability of our model predictions based on 
plausible ranges of the input parameters derived from 
various sources, we performed an uncertainty analy-
sis with 1000 simulations [26]. Under the Latin hyper-
cube sampling (LHS) scheme, a probability distribution 
is constructed for each input parameter that is not 
known with certainty. Input parameters that are known 
with large certainty, either because they are fixed val-
ues constructed for the simplicity of the model (such 
as population/cohort size) or because they are reliable 
values derived from large, nationally representative 
Indian survey datasets are excluded from the model. 
Table 4 describes the baseline values and the assumed 
range and distributions for those input parameters that 
are likely to be affected by uncertainty, either because 
they are aggregate, regional estimates not specific to 
India, or because they are based on local village-level 
field studies with small sample sizes that may not be 
representative of the country as a whole. In case of cur-
rent coverage rates, we consider two alternative aver-
age current coverage rates of 20  % (pessimistic case) 
and 50  % (optimistic case) in Table  4. We specified a 
plausible range of minimum and maximum values for 
the uncertain parameters based on available literature 
or on assumptions made by the working team. Figure 
A1 shows the summary statistics from the LHS scheme 
with 1000 simulations for three outcomes—DALY 
averted, OOP expenses averted and money metric 
value of insurance—in the form of box plots represent-
ing quartile values for each income quintile. Please see 
Additional file 1 for the box plots. We do not show the 
corresponding boxplots for cost-effectiveness ratio here 
since the ratio is constant across quintiles. The sum-
mary statistics for this outcome are included in Table 3. 
Tables  5, 6 present the values including means for all 
four outcomes in tabular form. Reducing current cov-
erage by half, for example, reduces the current averted 
burden (as well as the value of insurance) by 50 %, but 
also reduces the costs and averted private expenditure 
associated with current treatment by this proportion, 
thereby resulting in no change in cost-effectiveness. It 
is worth mentioning that the relatively larger variation 
across quintiles for value of insurance is most likely due 
to the variation in prevalence rates, which range from 
0.251 % (Q1) to 0.322 % (Q5). This variation in preva-
lence is due to the age distribution of the DLHS-3 sam-


























Fig. 2 Money metric value of insurance under UPF, by income quintile
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Discussion
While existing research considers the cost-effectiveness 
of schizophrenia treatment in low-resource settings 
including India, our paper considers the extension of 
the current literature to evaluate the cost-effectiveness 
of publicly financed schizophrenia treatment in India 
and includes the non-health financial benefits of UPF to 
private individuals or households. Our results show that 
when current coverage is extended to 80  % under UPF, 
health gains in terms of DALYs averted from UPF are 
the highest among the poor; however, these gains come 
at a higher cost for the poorest quintile, since UPF cov-
ers a larger proportion of this income group vis-à-vis the 
richest.
The money metric value of insurance is a quantifiable 
measure of financial protection under UPF and this ECEA 
illustrates that it is feasible to design essential packages 
of publicly financed health services to include financial 
protection as an additional outcome besides health gains. 
We see a relatively modest downward trend in the insur-
ance values from the lowest income quintile to the highest 
income quintile; risk protection from UPF would accrue 
primarily to low-income groups. Total value of insurance 
is USD $24,582 to one million population, of which, 30 % 
accrues to the poorest income quintile.
Finally, we offer a few caveats on the results. The model 
remains limited in scope because of the paucity of relia-
ble data for India on mental disorders and schizophrenia 
in particular. Many of the epidemiological and efficacy 
parameter values used in this analysis rely on regional 
(South Asia) estimates. Data on treatment costs come 
largely from the mhGAP costing tool, which is based 
on a small sample of individuals from a relatively small 
study site in India (Sehore, Madhya Pradesh); estimates 
on costs of services may therefore not be representa-
tive at the national level. Moreover, we did not estimate 
all potential costs incurred by service users, such as the 
transportation, time and opportunity costs involved in 
receiving treatment.
There are no reliable data on key input parameters 
disaggregated by income levels. For example, we expect 
treatment costs to vary by income but we do not have 
data on income-specific treatment costs. Likewise, we 
also expect treatment effectiveness and adherence rates 
to vary by income quintiles. Similar to treatment cov-
erage rates, adherence rate for poorer quintiles may be 
Table 4 Input parameters with uncertainty





Disability weight (residual) Uniform 0.58 0.76 0.40 [15]
Disability weight (acute) Uniform 0.76 0.89 0.57 [15]
Treatment efficacy (anti-psychotic + psychosocial treatment) Uniform 0.24 0.26 0.22 [13, 17, 18]
Treatment adherence rate Uniform 0.76 0.84 0.68 [19]
Total cost per case ($) Uniform 177.42 212.90 141.93 [13]
Current coverage rate by income quintile—pessimistic case
I Uniform 0.10 0.20 0.00
II Uniform 0.15 0.25 0.05
III Uniform 0.20 0.30 0.10
IV Uniform 0.25 0.35 0.15
V Uniform 0.30 0.40 0.20
Current coverage rate by income quintile—optimistic case
I Uniform 0.40 0.50 0.30
II Uniform 0.45 0.55 0.35
III Uniform 0.50 0.60 0.40
IV Uniform 0.55 0.65 0.45
V Uniform 0.60 0.70 0.50
Target coverage rate by income quintile
Quintiles I–V Uniform 0.80 0.90 0.70 Author’s assumption
Percentage of all costs that are Out Of Pocket (OOP) by income quintile
Quintiles I–V Uniform 0.70 0.80 0.60 Author’s assumption
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lower as low-income households may face additional 
constraints to access care and supply issues may affect 
availability of drugs at the health facility level; how-
ever, lack of data on variation of treatment adherence 
rates by income for mental disorders in India limits our 
analysis to assuming a constant adherence rate in the 
model.
A further concern is the use of DALYs as a measure of 
health outcome for schizophrenia treatment. Although 
DALYs are a useful measure of the efficiency of schizo-
phrenia care relative to other health investments, they 
do not deal with comorbidity and cannot reflect the 
effect of treatment on the patients’ families [17]. In 
this analysis, we only assessed the impact of treatment 
on reducing the non-fatal burden of diseases associ-
ated with schizophrenia (measured in terms of years 
lived with disability or YLD); although schizophrenia 
is clearly associated with excess mortality, effects on 
this dimension of disease burden (measured in terms 
of years of life lost) were not included since there is 
insufficient evidence to suggest that the psychosocial 
and pharmacological interventions modelled here lead 
directly to a reduction in mortality.
Lastly, although the paper extends standard cost-effec-
tiveness analysis to include certain financial outcomes, 
we do not account for non-health benefits of treatment 
Table 5 Summary statistics of Latin hypercube distribution for ECEA outcomes—pessimistic case
Outcome DALY averted
Income quintile I II III IV V Total
Minimum 20.97 19.37 19.23 17.31 17.56 111.52
1st quartile 33.18 31.46 30.64 29.70 30.01 160.00
Mean 39.02 37.27 36.29 35.26 35.66 183.50
Median 38.78 36.80 35.51 34.53 35.24 181.68
3rd quartile 44.02 42.56 41.31 40.04 40.78 205.15
Maximum 74.05 66.25 64.94 59.57 62.07 295.10
Outcome OOP expenses averted
Income quintile I II III IV V Total
Minimum ($) 31.861 31.607 33.301 36.283 41.366 198.745
1st quartile ($) 43.972 45.189 47.408 50.907 56.564 248.738
Mean ($) 49.884 51.277 54.128 57.447 63.880 276.617
Median ($) 49.281 50.822 53.314 56.710 63.165 275.072
3rd quartile ($) 55.488 56.774 60.124 63.478 70.511 304.159
Maximum ($) 73.910 77.080 80.511 84.425 94.717 369.918
Outcome Cost‑effectiveness ratio (USD/DALY averted)
Income quintile I II III IV V Total
Minimum ($) 940 940 940 940 940 940
1st quartile ($) 1.399 1.399 1.399 1.399 1.399 1.399
Mean ($) 1.641 1.641 1.641 1.641 1.641 1.641
Median ($) 1.605 1.605 1.605 1.605 1.605 1.605
3rd quartile ($) 1.861 1.861 1.861 1.861 1.861 1.861
Maximum ($) 2.847 2.847 2.847 2.847 2.847 2.847
Outcome Value of insurance
Income quintile I II III IV V Total
Minimum ($) 1 331 551 618 409 3.335
1st Quartile ($) 901 1.189 1.354 1.354 880 6.825
Mean ($) 2.015 1.974 2.046 1.965 1.195 9.194
Median ($) 1.772 1.757 1.850 1.839 1.144 8.819
3rd Quartile ($) 2.848 2.600 2.580 2.411 1.446 11.111
Maximum ($) 7.945 6.717 5.902 5.211 2.969 22.213
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in the form of workforce and household productivity 
gains. A cost-benefit analysis would be needed to meas-
ure those effects.
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